Introduction {#tca12314-sec-0005}
============

Lung cancer is currently the leading cause of cancer‐related death in China. It is generally accepted that early diagnosis and treatment of patients with non‐small cell lung cancer (NSCLC) has a very important impact on their prognosis. Many researchers have focused their studies on lung cancer sized 2 cm or less.[1](#tca12314-bib-0001){ref-type="ref"}, [2](#tca12314-bib-0002){ref-type="ref"}, [3](#tca12314-bib-0003){ref-type="ref"} Mediastinal lymph node metastasis can sometimes be detected in patients with tumors smaller than 2 cm, which is why many reports suggest that systematic mediastinal lymph node dissection should be performed, even in these patients.[4](#tca12314-bib-0004){ref-type="ref"}, [5](#tca12314-bib-0005){ref-type="ref"} Recent reports have mainly focused on whether lobectomy or sublobectomy and systematic mediastinal lymphadenectomy or mediastinal lymph node sampling should be used to cure patients with T1a‐stage.[6](#tca12314-bib-0006){ref-type="ref"}, [7](#tca12314-bib-0007){ref-type="ref"}, [8](#tca12314-bib-0008){ref-type="ref"} However, there have been few observational studies on the clinical features of tumors in the T1aN2M0 subgroup. The factors that are associated with mediastinal lymph node metastasis in T1a lung cancer are currently unclear. Useful markers that could be utilized to guide surgical procedures may exist, such as the extent of mediastinal dissection.

The purpose of the present retrospective study was to conduct a comprehensive observation of the clinical features of T1aN2M0 stage NSCLC.

Patients and methods {#tca12314-sec-0006}
====================

Patients {#tca12314-sec-0007}
--------

From November 2008 to May 2013, 598 patients with pulmonary lesions sized 2 cm or less who visited the Shanghai Cancer Center were included in the study. Clinical and pathologic data, including gender, smoking status, age, pathologic stage, primary tumor site, tumor location, pleural invasion, histology type, gene status, single or multiple station N2, skip N2, and number of positive lymph nodes were prospective collected. Of the 598, 498 T1a stage NSCLC patients underwent a lobectomy or segmentectomy with systematic nodal resection for primary lung cancer. Exclusion criteria included patients with: benign pulmonary masses; tumors of Tx, T0, or Tis‐stage; or distant metastases. Evaluation before surgery included physical examination, computed tomography (CT) of the chest, two‐dimensional ultrasound of the abdomen and supraclavicular and axillary lymph nodes, magnetic resonance imaging (MRI) of the brain, bone scintigraphy examinations, and a pulmonary function test. Positron emission tomography (PET) scans and endobronchial ultrasound‐guided transbronchial needle aspiration (EBUS‐TBNA) were also performed in some patients, but were not part of the routine examination. If a pulmonary lesion had standardized uptake values (SUV) of \>2.5 on PET imaging, it was considered a malignant tumor.

The histopathologic types of these patients\' tumors were confirmed by two pathologists after surgery. Lung cancer stage was based on the 2009 7th edition of the Tumor Node Metastasis (TNM) Classification.

Methods {#tca12314-sec-0008}
-------

Lymph nodes were classified into two groups according to their location. Mediastinal lymph nodes included lymph nodes of stations 1--9. Intrapulmonary lymph nodes included those of stations 10--14. Patients with mediastinal lymph nodes larger than 1 cm on the short axis underwent EBUS‐TBNA. If mediastinal lymph node disease was confirmed, the patient received neoadjuvant chemotherapy and was excluded from the study. During surgery, if the tumor specimen was confirmed to be malignant and was not diagnosed from frozen sections as carcinoma in situ, systematic lymph node dissection was then performed. Systematic lymph node dissection on the right mediastinum includes complete resection of stations 2R, 4R, 7, 8, and 9, while on the left includes removal of stations 4L, 5, 6, 7, 8, and 9. All 498 patients were divided into three groups of patients at T1aN2M0, T1aN0M0, and T1aN1M0 stages according to lymph node metastasis status. Patients with positive lymph nodes received chemotherapy three weeks after surgery. All patients were followed up through direct patient or family contact. Data for each group, including gender, age, smoking history, primary tumor site, tumor location, pleural invasion, tumor size, histology type, gene status, number of positive lymph nodes, skip N2, single or multiple station N2, progression‐free survival (PFS), and overall survival (OS), were collected. PFS duration was defined as the time between the date of surgery and the date of the first recurrence or last follow‐up. OS duration was defined as the interval from surgery to death or to the date of the last follow‐up.

Statistical analysis {#tca12314-sec-0009}
--------------------

All statistical analyses were performed using SPSS 17.0 (SPSS Inc., Chicago, IL, USA). Patient characteristic data were expressed as means and standard deviations. A Pearson\'s χ2 test was used to test for differences in categorical variables and the *t*‐test was used for quantitative data. Survival curves were plotted according to the Kaplan--Meier method and compared with the log‐rank test. Multivariable logistic regression analyses were used to determine the factors that influenced lymph node metastasis. Cox regression analyses were used to determine the factors that influenced PFS and OS. *P* values of less than 0.05 were considered statistically significant.

Results {#tca12314-sec-0010}
=======

Patient characteristics {#tca12314-sec-0011}
-----------------------

There were 498 patients included in this retrospective study. Tumor status of the patients studied included: 64 (12.9%) at T1aN2M0, 400 (80.3%) at T1aN0M0, and 34 patients (6.8%) at T1aN1M0, according to the 2009 7th edition of the TNM Classification. Patient characteristics are shown in Table [1](#tca12314-tbl-0001){ref-type="table-wrap"}. Tumor size in the T1N0M0 group was smaller than in the T1aN2M0 (*P* \< 0.01) and T1aN1M0 groups (*P* \< 0.01). Regarding tumor size distribution, the ratio of tumor diameters greater than 1.5 cm but less than or equal to 2 cm in the T1aN0M0 group was less than that of the T1aN2M0 (*P* \< 0.01) and T1aN1M0 groups (*P* \< 0.05). The ratio of pleural invasion in the T1aN2M0 group was higher than in the T1aN0M0 group (*P* \< 0.05). The ratio of adenocarcinoma in the T1aN2M0 group (95.3%) was higher than that of the T1aN0M0 group (90.8%). In the subgroup of adenocarcinoma cases, the ratios of acinar adenocarcinoma and solid adenocarcinoma in the T1aN2M0 group (65.6%, 21.3%) were higher than those in the T1aN0M0 (48.8%, 6.9%) and T1aN1M0 groups (48.1%, 14.8%). The number of single‐station N2 and skip N2 of the T1aN2M0 group was 37 and 27, respectively. The number of positive lymph nodes in the T1aN2M0 group was much higher than in the other two groups. In regard to gene status, the ratio of echinoderm microtubule associated protein like 4‐anaplastic lymphoma kinase (*EML4‐ALK*) fusion in the T1aN0M0 group was lower than the T1aN2M0 (*P* \< 0.05) and T1aN1M0 groups (*P* \< 0.01; Table [1](#tca12314-tbl-0001){ref-type="table-wrap"}).

###### 

Patient characteristics (*n* = 498)

                                  T1aN2M0     T1aN0M0     T1aN1M0     *P*
  ------------------------------- ----------- ----------- ----------- -------------
  Gender                                                              0.484/0.004
  Male                            26          158         22          
  Female                          38          242         12          
  Age                             59.2±10.1   59.5±14.5   57.7±7.2    0.906/0.473
  Smoking history                                                     0.092/0.003
  Smoker                          22          102         17          
  Non‐smoker                      42          298         17          
  Tumor location                                                      0.241/0.598
  Right upper lobe                17          137         11          
  Right middle lobe               6           29          2           
  Right lower lobe                8           79          6           
  Left upper lobe                 21          90          11          
  Left lower lobe                 12          65          4           
  Primary tumor site                                                  0.259/0.152
  Central                         3           32          5           
  Peripheral                      61          368         29          
  Tumor size(cm)                  1.70±0.32   1.56±0.39   1.77±0.32   0.004/0.001
  Tumor size distribution                                             0.001/0.013
  d≤1                             2           71          1           
  1\<d≤1.5                        24          144         8           
  1.5\<d≤2                        38          185         25          
  Histology type                                                      0.067/0.051
  Squamouscell carcinoma          1           33          7           
  Adenosquamous carcinoma         2           4           0           
  Adenocarcinoma                  61          363         27          0.000/0.006
  IMA                             2           16          1           
  MIA                             0           15          0           
  Lepidic predominant             0           83          1           
  Acinar predominant              40          177         13          
  Papillary predominant           6           44          6           
  Micropapillary predominant      0           3           2           
  Solid predominant               13          25          4           
  Pleural invasion (+/−)          20/44       80/320      4/30        0.034/0.174
  Gene status                                                         
  EGFR (+/−)                      40/24       270/130     16/18       0.257/0.015
  KRAS (+/−)                      4/60        29/371      4/30        0.512/0.252
  HER2 (+/−)                      0/64        6/394       0/34        0.108/0.611
  BRAF (+/−)                      0/64        3/397       0/34        0.640/0.782
  ALK (+/−)                       6/58        10/390      5/29        0.014/0.004
  RET (+/−)                       2/62        7/393       0/34        0.359/0.563
  ROS1 (+/−)                      0/64        2/398       1/33        0.743/0.218
  Single or multiple station N2                                       
  (single/multiple)               37/27       --          --          
  Skip N2 (+/−)                   27/37       --          --          
  Number of positive LN           5.3±4.7     0           1.8±1.1     0.000/0.000

ALK, anaplastic lymphoma kinase; BRAF, v‐Raf murine sarcoma viral oncogene homolog B; d, diameter; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; IMA, invasive mucinous adenocarcinoma; KRAS, v‐Ki‐ras2 Kirsten rat sarcoma viral oncogene homolog; LN, lymph node; MIA, minimally invasive adenocarcinoma; RET, ret proto‐oncogene; ROS, ROS proto‐oncogene 1.
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Progression‐free survivial (PFS) and overall survival (OS) {#tca12314-sec-0012}
----------------------------------------------------------

The median follow‐up time was 33.5 months (range 5.1--81.5). The five‐year OS rate of all 498 patients was 95.8%, while that of patients at T1aN2M0, T1aN0M0, and T1aN1M0 stages were 89.1%, 97.3%, and 85.3%, respectively (*P* \< 0.01).The five‐year PFS rate of patients at T1aN2M0, T1aN0M0, and T1aN1M0 stages was 68.8%, 90.3%, and 76.5%, respectively(*P* \< 0.01, Figs [1](#tca12314-fig-0001){ref-type="fig"} and [2](#tca12314-fig-0002){ref-type="fig"}).
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Factors affecting lymph node metastasis, OS, and PFS {#tca12314-sec-0013}
----------------------------------------------------

Tumor size distribution, history type, gender, pleural invasion positivity, and ALK positivity were statistically significantly associated with mediastinal lymph node metastases in the T1a stage in univariate analyses. Multivariable logistic regression analysis of these five factors showed that only gender, tumor size distribution, and histology type were significant predictors of mediastinal lymph node metastases. In the adenocarcinoma subgroup, acinar predominant and solid predominant tumors were significant predictors of mediastinal lymph node metastases.

In the T1aN2M0 stage, the number of positive lymph nodes, smoking history, and gender were statistically significantly associated with OS in univariate analysis, while for PFS, the significant factors were positive lymph nodes, smoking history, gender, and primary tumor site. Only the number of positive lymph nodes was significantly associated with OS and PFS rates in multivariate analysis (Table [2](#tca12314-tbl-0002){ref-type="table-wrap"}).

###### 

Multivariable logistic regression analyses for factors affecting mediastinal lymph node metastases. Cox regression analyses for OS and PFS in T1a stage

  Variable                                                           UVA     MVA                                   
  ------------------------------------------------------------------ ------- --------------------- --------------- -------
  Factors affecting mediastinal lymph node metastases in T1a stage                                                 
  Gender                                                             0.000   0.404                 0.297--0.548    0.000
  Tumor size distribution                                            0.012   2.006                 1.247--3.227    0.004
  Histology type                                                     0.000   1.297                 1.102--1.528    0.002
  Adenocarcinoma subtype                                                                                           
  Acinar predominant                                                 0.005   2.643                 1.451--4.812    0.001
  Solid predominant                                                  0.001   2.588                 1.171--5.718    0.019
  IMA                                                                0.892   Not included in MVA                   
  MIA                                                                0.999   Not included in MVA                   
  Lepidic predominant                                                0.996   Not included in MVA                   
  Papillary predominant                                              0.649   Not included in MVA                   
  Micropapillary predominant                                         0.999   Not included in MVA                   
  Pleural invasion+                                                  0.031   1.713                 0.906--3.238    0.098
  ALK+                                                               0.035   2.734                 0.909--8.225    0.073
  EGFR+                                                              0.745   Not included in MVA                   
  Age                                                                0.964   Not included in MVA                   
  Smoking history                                                    0.249   Not included in MVA                   
  Tumor location                                                     0.139   Not included in MVA                   
  Primary tumor site                                                 0.323   Not included in MVA                   
  Factors affecting OS in T1aN2M0 stage subgroup.                                                                  
  Number of positive LNs                                             0.012   1.143                 1.002--1.143    0.047
  Smoking history                                                    0.039   1.996                 0.268--14.890   0.500
  Gender                                                             0.037   0.235                 0.017--3.250    0.280
  Single or multiple station N2                                      0.110   Not included in MVA                   
  Skip N2                                                            0.253   Not included in MVA                   
  Tumor size distribution                                            0.390   Not included in MVA                   
  Age                                                                0.195   Not included in MVA                   
  Tumor location                                                     0.432   Not included in MVA                   
  Histology type                                                     0.243   Not included in MVA                   
  Primary tumor site                                                 0.304   Not included in MVA                   
  Pleural invasion+                                                  0.484   Not included in MVA                   
  EGFR+                                                              0.977   Not included in MVA                   
  ALK+                                                               0.560   Not included in MVA                   
  Factors affecting PFS in T1aN2M0 stage subgroup.                                                                 
  Number of positive LNs                                             0.006   1.106                 1.005--1.217    0.039
  Smoking history                                                    0.04    1.563                 0.536--4.559    0.413
  Gender                                                             0.027   0.701                 0.224--2.192    0.541
  Primary tumor site                                                 0.008   0.279                 0.075--1.035    0.056
  Single or multiple station N2                                      0.116   Not included in MVA                   
  Skip N2                                                            0.679   Not included in MVA                   
  Tumor size distribution                                            0.236   Not included in MVA                   
  Age                                                                0.096   Not included in MVA                   
  Tumor location                                                     0.19    Not included in MVA                   
  Histology type                                                     0.498   Not included in MVA                   
  Pleural invasion+                                                  0.098   Not included in MVA                   
  EGFR+                                                              0.985   Not included in MVA                   
  ALK+                                                               0.408   Not included in MVA                   

The reference groups of the various factors were, male(gender), d ≤ 1 (tumor size distribution), non‐smoker (smoking history), no invasion(pleural invasion), ALK‐(ALK+), EGFR‐(EGFR+), right upper lobe (tumor location), central (primary tumor site), squamous cell carcinoma (history type),single(Single or multiple station N2) and noskip N2(skip N2).ALK, anaplastic lymphoma kinase; CI, confidence interval; d, diameter; EGFR, epidermal growth factor receptor; IMA, invasive mucinous adenocarcinoma; LN, lymph node; MIA, minimally invasive adenocarcinoma; MVA, multivariate analysis; UVA, univariate analysis.
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Discussion {#tca12314-sec-0014}
==========

In the 2009 7th edition of the TNM Classification, T1 stage tumors were subdivided into tumors at T1a and T1b stages. Current research has focused on the treatment and prognosis of NSCLC patients with T1a stage. Consequently, there are few clinical analyses of lung cancer at T1aN2M0 stage.

Because mediastinal lymph node metastasis has a significant impact on prognosis in NSCLC patients, many researchers have suggested that systematic lymph node dissection is necessary for T1a stage NSCLC patients.[9](#tca12314-bib-0009){ref-type="ref"}, [10](#tca12314-bib-0010){ref-type="ref"}, [11](#tca12314-bib-0011){ref-type="ref"} However, researchers have also reported that the outcomes of T1a patients who underwent lymph node sampling were not significantly different from patients who underwent systematic lymph node dissection.[12](#tca12314-bib-0012){ref-type="ref"}, [13](#tca12314-bib-0013){ref-type="ref"} We found that these researchers seldom analyzed the impact of tumor size and histology type on mediastinal lymph node metastases. Table [2](#tca12314-tbl-0002){ref-type="table-wrap"} shows the results of multivariable logistic regression analysis, in which gender, tumor size distribution, and histology type are significant predictors of mediastinal lymph node metastases in patients with T1a stage tumors. This means that during surgery, systematic lymph node dissection may be necessary for patients with T1a stage cancer if the patient is female, the tumor diameter is greater than 1 cm, or the tumor specimen is confirmed by frozen sections to be adenocarcinoma. Further research is required to determine whether the prognosis of patients who undergo systematic lymph node dissection is better than those who undergo lymph node sampling.

Tumor size is considered to be associated with the prognosis of T1a stage cancer NSCLC patients. Shi *et al*. reported five‐year survival rates in patients with tumors 1.6--2.0 cm, 1.0--1.5 cm, and less than 1.0 cm in diameter of 80.20%, 85.07%, and 100%, respectively; the differences between these were significant.[4](#tca12314-bib-0004){ref-type="ref"} Kudo *et al*. determined that in T1a stage NSCLC patients, tumor size is a prognostic factor.[14](#tca12314-bib-0014){ref-type="ref"} On the contrary, Kobayashi *et al*. and Nitadori *et al*. suggested that tumor size was not significantly associated with the OS of patients with T1a stage cancer.[15](#tca12314-bib-0015){ref-type="ref"} ^,^ [16](#tca12314-bib-0016){ref-type="ref"} However, these researchers did not subdivide their cases according to the status of lymph node metastasis.

There have been few detailed analyses to determine whether tumor size is a prognostic factor in patients with T1aN2M0 stage cancer. Our results determined that tumor size distribution was significantly associated with mediastinal lymph node metastasis in patients with T1a stage cancer (Table [2](#tca12314-tbl-0002){ref-type="table-wrap"}). However, for patients in the T1aN2M0 subgroup, tumor size distribution was not a significant predictor of OS and PFS, which might mean that postoperative follow‐up for patients with tumors \> 1 cm in diameter should be no different than that for patients with tumors ≤ 1 cm. Because there was a small number of T1aN2M0 cases in our sample, further research is required to determine whether tumor size is a prognostic factor for T1aN2M0 stage patients.

The number of positive lymph nodes is considered to be a prognostic factor for NSCLC. Jonnalagadda *et al*. performed an analysis of patients with N1 NSCLC and found that the number of positive lymph nodes is an independent prognostic factor of survival in these patients.[17](#tca12314-bib-0017){ref-type="ref"} Jeon and Dehing‐Oberije expressed a similar view in their research on clinical IA stage NSCLC patients and patients with inoperable NSCLC treated with (chemo)radiation.[18](#tca12314-bib-0018){ref-type="ref"}, [19](#tca12314-bib-0019){ref-type="ref"} However, other authors have expressed different opinions. Haney *et al*. showed that the number of positive lymph nodes was not significantly associated with the prognosis of patients with surgically resected stage II NSCLC.[20](#tca12314-bib-0020){ref-type="ref"} None of these researchers considered the impact of the number of positive lymph nodes in the T1aN2M0 subgroup. Our research showed that the number of positive lymph nodes was a significant predictor of not only OS, but also PFS, in patients with T1aN2M0 stage NSCLC, which might mean that a longer postoperative follow‐up is needed for patients with greater numbers of positive lymph nodes.

Epidermal growth factor receptor (*EGFR*) mutations and *ALK* fusions are thought to be associated with the prognosis of NSCLC patients. Jeon *et al*. indicated that the presence of an *EGFR* mutation is an independent prognostic factor for PFS, and selecting patients for EGFR‐TKI therapy according to *EGFR* mutation status may lead to better prognoses in patients with recurrent pulmonary adenocarcinoma.[21](#tca12314-bib-0021){ref-type="ref"} Li *et al*. performed an analysis on *EGFR* T790M mutations in NSCLC patients and found that although primary *EGFR* T790M mutations are rare in NSCLC cases, they are a predictor of a poorer prognosis.[22](#tca12314-bib-0022){ref-type="ref"} However, there are also different points of view about the relationship between *EGFR* mutation status and NSCLC prognosis. Fang and Wang analyzed the relevant research of the past 20 years and concluded that the prognostic and predictive value of *EGFR* mutation status in NSCLC remains uncertain.[23](#tca12314-bib-0023){ref-type="ref"} We found that most of these studies had not considered the T1aN2M0 subgroup. Our research showed that *EGFR* and *ALK* status were not significant predictors of OS and PFS rates in patients of the T1aN2M0 subgroup, nor were they independent predictors of mediastinal lymph node metastasis. Existing research has confirmed that molecular‐targeted therapy is effective for NSCLC patients with EGFR and ALK‐positive tumors.[24](#tca12314-bib-0024){ref-type="ref"}, [25](#tca12314-bib-0025){ref-type="ref"} Even if EGFR and ALK status are not independent predictors of OS in patients with T1aN2M0 stage cancer, genetic testing may still be very important for the individualized treatment of these patients.

In conclusion, we found that patients with T1aN2M0 stage NSCLC had poorer PFS and OS rates than those with T1aN0M0 or T1aN1M0 stage NSCLC. Gender, tumor size distribution, and histology type were independent factors of mediastinal lymph node metastasis in T1a stage patients. The number of positive lymph nodes was significantly associated with OS and PFS of patients in T1aN2M0 stage. The next step is to evaluate the best treatment for T1aN2M0 NSCLC patients.
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